Oncology · ChemotherapyRegulatory Approvalregulatorymid-term

FDA Grants Approval Status for Capecitabine ANDA204741 by Amneal Pharmaceuticals

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/5/2026, 12:32:31 AM

Assessment confidence: 62% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval status for Amneal's ANDA204741 for Capecitabine is significant as it strengthens Amneal's competitive position in the oncology market. This development necessitates a review of market strategies for existing Capecitabine alternatives to mitigate potential market share loss. Regulatory context from FDA (FDA AP — CAPECITABINE (SUPPL)) supports the near-term read. Assessment grounded in 26 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for Capecitabine alternatives. The strongest clinical anchor is A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Chemotherapy, 6 regulatory and 4 competitive items passed relevance filtering for Amneal Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Approves Lutetium Lu 177 VIPIVOTIDE for Metastatic Prostate Cancer. This approval status may enhance Amneal's position in the oncology market, particularly in the generic chemotherapy segment.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — CAPECITABINE (SUPPL) (FDA). Entity match (capecitabine); Regulatory pathway relevance (nda). While the approval status is a positive step, the final approval and market launch timeline remain critical for assessing full regulatory implications.

Key Risks

Elevated medium regulatory exposure for Amneal Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval may lead to increased competition in the generic chemotherapy market, potentially impacting pricing and market share for other Capecitabine products.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for Capecitabine alternatives.

What Would Change This Assessment

This becomes more urgent if Monitor for the final approval and market launch timeline of ANDA204741.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — CAPECITABINE (SUPPL)
FDAhigh relevance
Entity match (capecitabine); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CAPECITABINE (SUPPL)
FDAhigh relevance
Entity match (capecitabine); Regulatory pathway relevance (nda)
FDA document
View source
Advancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs - 08/27/2026
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Verified Clinical Benefit | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Other | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source

A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Met
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Electroacupuncture and Exercise for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves Lutetium Lu 177 VIPIVOTIDE for Metastatic Prostate Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Novartis)
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts NDA for Trabectedin by Apotex
Humanexa Signalsmedium relevance
Moderate corpus alignment

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Protocol for a cohort study: evaluating the effect of neoadjuvant immunochemotherapy on intraoperative remifentanil consumption during IoC2-guided anesthesia in elderly patients with esophageal cancer
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Early prediction of minimal residual disease in colorectal cancer via SEPTIN9 methylation status in circulating tumor DNA.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Feasibility and safety of recombinant zoster vaccination in patients undergoing active cancer treatments: A real-world single-center experience.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Amneal Pharmaceuticals
Capecitabine

Commercial impact

medium

The approval may lead to increased competition in the generic chemotherapy market, potentially impacting pricing and market share for other Capecitabine products.

Regulatory impact

medium

While the approval status is a positive step, the final approval and market launch timeline remain critical for assessing full regulatory implications.

What to watch

Monitor for the final approval and market launch timeline of ANDA204741.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.